
Amir H. Lebastchi, MD, provides perspectives on the VIOLETTE study and underscores the importance of future head-to-head trials to gain a deeper understanding of various treatment approaches.

Amir H. Lebastchi, MD, provides perspectives on the VIOLETTE study and underscores the importance of future head-to-head trials to gain a deeper understanding of various treatment approaches.

Dr. Amir H. Lebastchi elaborates on his approach to integrating MRI and ultrasound fusion-based technology for guiding treatment selection and tailoring therapy for patients with prostate cancer.

Amir H. Lebastchi, MD, outlines his general strategy for active surveillance in prostate cancer patients, emphasizing the role of MRI and fusion-guided prostate biopsy.

Dr. Amir H. Lebastchi reviews retrospective data comparing software-based and cognitive-based fusion biopsy approaches, providing valuable insights into the findings.

Amir H. Lebastchi, MD, explores the evolving landscape in the context of fusion-guided prostate biopsy methods.

Dr Amir H. Lebastchi delves into the latest advancements and evolving tactics in the field of prostate cancer biopsy and diagnostic procedures.

Amir H. Lebastchi, MD, provides insights into the current prostate cancer landscape, emphasizing the importance of prostate cancer screening and early detection.

Pinto and colleagues provide an overview of MRI/TRUS fusion-guided transperineal biopsy utilizing the UroNav platform.

Published: April 20th 2020 | Updated: